Jim Simons Galecto, Inc. Transaction History

Renaissance Technologies LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$0.47 - $0.76 $148 - $240	317 Added 0.05%	579,300 $272,000
Q1 2024 May 13, 2024	BUY	$0.6 - $0.89 $103,209 - $153,093	172,015 Added 42.27%	578,983 $452,000
Q4 2023 Feb 13, 2024	BUY	$0.52 - $0.78 $104,971 - $157,457	201,868 Added 98.42%	406,968 $293,000
Q3 2023 Nov 14, 2023	BUY	$0.56 - $3.17 $21,973 - $124,387	39,239 Added 23.66%	205,100 $148,000
Q2 2023 Aug 11, 2023	BUY	$1.68 - $2.84 $16,398 - $27,721	9,761 Added 6.25%	165,861 $418,000
Q1 2023 May 12, 2023	BUY	$1.21 - $2.86 $2,541 - $6,006	2,100 Added 1.36%	156,100 $311,000
Q4 2022 Feb 13, 2023	SELL	$1.06 - $58.5 $26,818 - $1.48 Million	-25,300 Reduced 14.11%	154,000 $177,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $60.0 $107,183 - $4.04 Million	-67,411 Reduced 27.32%	179,300 $339,000
Q2 2022 Aug 12, 2022	BUY	$1.22 - $2.74 $25,067 - $56,298	20,547 Added 9.09%	246,711 $427,000
Q1 2022 May 13, 2022	SELL	$1.72 - $3.31 $6,941 - $13,359	-4,036 Reduced 1.75%	226,164 $498,000
Q4 2021 Feb 11, 2022	BUY	$2.3 - $3.58 $292,790 - $455,734	127,300 Added 123.71%	230,200 $698,000
Q3 2021 Nov 12, 2021	BUY	$3.59 - $5.0 $226,888 - $316,000	63,200 Added 159.19%	102,900 $369,000
Q2 2021 Aug 13, 2021	BUY	$4.63 - $8.0 $183,811 - $317,600	39,700 New	39,700 $201,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $119M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.